New results from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study showed that a combination of pembrolizumab and concurrent chemoradiotherapy (CCRT) continues to improve progression-free survival (PFS) in locally advanced cervical cancer. Initial results found that among 1060 participants in 30 countries, the pembrolizumab plus CCRT group conferred better PFS at 24 months than the placebo plus CCRT […]
The post Pembrolizumab Continues to Improve PFS in Cervical Cancer first appeared on News Health.
Author : News Health
Publish date : 2025-03-18 12:44:00
Copyright for syndicated content belongs to the linked Source.